Pictured: AbbVie’s corporate office in South San Francisco, California/iStock, vzphotos
Despite hitting the market more than a year ago with steep discounts, biosimilars for AbbVie’s blockbuster arthritis treatment Humira (adalimumab) have managed to take only 4% of the market share away from the branded…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
